-
61.
公开(公告)号:US20140255398A1
公开(公告)日:2014-09-11
申请号:US14347448
申请日:2012-09-28
IPC分类号: C07K16/28
摘要: The present inventors have discovered that in living organisms that have received an antigen-binding molecule containing an antigen-binding domain whose binding activity to an antigen changes depending on ion concentration conditions and containing an FcRn-binding domain having FcRn-binding activity in a neutral pH range, immune responses to the antigen are induced. Furthermore, the present inventors have discovered that in living organisms that have received an antigen-binding molecule containing an antigen-binding domain whose binding activity to an antigen changes depending on ion concentration conditions and containing an FcRn-binding domain having FcRn-binding activity in a neutral pH range, immune responses to the antigen are induced, and also the antigen-binding molecule has cytotoxicity or antiproliferative action against cancer cells, foreign biological species, or such that express the antigen to which the antigen-binding molecule binds.
摘要翻译: 本发明人已经发现,在已经接受含有抗原结合结构域的生物体中,所述抗原结合分子含有与抗原结合的抗原依赖于离子浓度条件而变化,并且含有在中性中具有FcRn结合活性的FcRn结合结构域 诱导pH范围,对抗原的免疫应答。 此外,本发明人已经发现,在已经接受含有抗原结合结构域的抗原结合分子的活生物体中,所述抗原结合结构域与抗原的结合活性根据离子浓度条件而变化,并且含有具有FcRn结合活性的FcRn结合结构域 中性pH范围,诱导对抗原的免疫应答,并且抗原结合分子对癌细胞,外来生物物种或表达抗原结合分子所结合的抗原具有细胞毒性或抗增殖作用。
-
公开(公告)号:US20130336963A1
公开(公告)日:2013-12-19
申请号:US13889512
申请日:2013-05-08
发明人: Tomoyuki Igawa , Shinya Ishii , Atsuhiko Maeda , Takashi Nakai
CPC分类号: C12N15/1037 , A61K39/12 , A61K39/145 , A61K2039/505 , A61K2039/544 , A61K2039/545 , A61K2039/552 , C07K16/244 , C07K16/248 , C07K16/2866 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C12N2760/16111 , C12N2760/16134 , C12N2770/20071 , G01N33/6854 , G01N2500/00
摘要: The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen.
-